Cwp84 Antigen Immunoassay for Rapid C. difficile Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting Clostridium difficile (C. difficile) in stool samples are either time-consuming, costly, or lack differentiation between toxigenic and non-toxigenic strains, and existing antibody-based tests face challenges with sensitivity due to interfering substances and antigen variability.
Innovation Solution
The use of Cell Wall Protein 84 (Cwp84) as a marker in immunoassays, either alone or in combination with other C. difficile proteins like GDH, to enhance the detection sensitivity and specificity of C. difficile, leveraging its conservation among strains and up-regulation by antibiotics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ethanol shock culture method is used to detect C. difficile, then sensitivity is high, but time consumption increases (up to 72 hours)
Solution Approach 1:
The patent extracts and detects a specific antigen (C. difficile antigen) directly from stool samples using immunoassay technology, bypassing the lengthy culture process. This extraction approach allows rapid detection within hours rather than days while maintaining high sensitivity through specific antibody-antigen binding.
Solution Approach 2:
The patent replaces the mechanical/biological culture system with an immunoassay system that uses antibody-antigen binding reactions. This substitution enables rapid detection without requiring bacterial cultivation, reducing time from 72 hours to a few hours while preserving detection accuracy.
2Productivity
If antibody-based tests are used to detect C. difficile, then rapid detection is achieved, but sensitivity decreases due to interfering substances and antigen variability
Solution Approach 1:
The patent optimizes immunoassay parameters including antibody selection, coating conditions, and detection thresholds to enhance sensitivity. By carefully controlling assay conditions and using highly specific monoclonal antibodies, the test achieves both rapid detection and high sensitivity despite the presence of interfering substances in stool samples.
Solution Approach 2:
The patent uses specific monoclonal antibodies as intermediaries that selectively bind to C. difficile antigens, distinguishing them from interfering substances. These antibody intermediaries enable specific detection of the target pathogen while ignoring other components in the complex stool sample matrix.
3Productivity
If existing antibody-based tests are used, then rapid detection is possible, but differentiation between toxigenic and non-toxigenic strains is lacking
Solution Approach 1:
The patent employs multiple specific monoclonal antibodies that target different antigens or epitopes on C. difficile, enabling differentiation between toxigenic and non-toxigenic strains. By segmenting the detection approach into multiple specific antibody-antigen interactions, the test provides both rapid detection and strain characterization information.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Cwp84-based method demonstrates high sensitivity and specificity, capable of detecting both toxigenic and non-toxigenic strains, with a detection limit of 0.2 ng/mL and no cross-reactivity with other bacteria, improving upon existing tests by providing rapid and cost-effective point-of-care diagnostics.
Implementation Method 1
The present invention is directed to test methods for detecting C. difficile in patients based on the presence of marker proteins derived from C. difficile. In particular, a new antigen marker, Cell Wall Protein 84 (Cwp84) may be used in immunoassays for the detection of C. difficile.
Data Source
AI summary
Accurate and fast detection of the presence of Clostridium difficile (C. difficile) disease is crucial for the proper treatment of patients with C. difficile infection. Present tests detecting the presence of C. difficile disease are fast and cost effective, but are not very sensitive. Using an ELISA including Cell Wall Protein 84 (Cwp84) increases the sensitivity of the ELISA. Cwp84 may be used alone or in combination with other markers to support a diagnosis of C. difficile-associated disease.